Bill Sponsor
House Bill 1117
118th Congress(2023-2024)
Advancing Safe Medications for Moms and Babies Act of 2023
Introduced
Introduced
Introduced in House on Feb 21, 2023
Overview
Text
Introduced
Feb 21, 2023
Latest Action
Mar 3, 2023
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1117
Congress
118
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Florida
Democrat
California
Democrat
Illinois
Democrat
Illinois
Democrat
Massachusetts
Democrat
Minnesota
Republican
Nebraska
Democrat
New Hampshire
Democrat
New Hampshire
Democrat
New Jersey
Democrat
New Jersey
Democrat
New York
Democrat
North Carolina
Democrat
North Carolina
Democrat
North Carolina
Republican
Pennsylvania
Democrat
Pennsylvania
Democrat
Washington
Democrat
Wisconsin
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Advancing Safe Medications for Moms and Babies Act of 2023

This bill establishes programs and requirements to support the inclusion of pregnant and lactating women in clinical research.

For example, the bill requires the Department of Health and Human Services to align the Food and Drug Administration's regulations for human subjects in clinical trials with other departmental regulations for pregnant women in clinical research.

The bill also establishes (1) a national online clearinghouse with information about clinical trials that enroll pregnant and lactating women, (2) an advisory committee to help coordinate federal activities with respect to clinical research for pregnant and lactating women, and (3) an educational campaign on the importance of including pregnant and lactating women in clinical research.

The National Institutes of Health must also prioritize certain research projects on new and existing medications for pregnant and lactating women based on need, feasibility, and the potential impact of the research.

Text (1)
February 21, 2023
Actions (3)
03/03/2023
Referred to the Subcommittee on Health.
02/21/2023
Referred to the House Committee on Energy and Commerce.
02/21/2023
Introduced in House
Graphics
H.R.1117 118 Advancing Safe Medications for Moms and Babies Act of 2023
Public Record
Record Updated
Apr 12, 2024 4:05:22 AM